GWOXI was established in 2004 as a biotech new drug company based on stem cell technology. Apply stem cell technology to regenerative medicine and health care to develop testing service and new drug products. We have been established the production technology platform of pharmaceutical-grade adipose-derived stem cell products, quality testing serves of clinical cellular products, pharmaceutical-grade stem cell storage service and a number of stem cell drug. For instance, GXHPC1 (Indication: liver cirrhosis), GXNPC1 (Indication: chronic stroke), GXCPC1 (Indication: osteoarthritis) and GXIPC1 (Indication: diabetes) are ongoing clinical trial in Taiwan or Vietnam. We are committed to continuing to develop stem cell therapy technologies and capabilities that have broad potential of commercial applications and meet the unmet medical needs.